$1.59 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | RayzeBio Inc | $53,713,522 | – | 2,419,528 | +100.0% | 3.39% | – | |
| ELAN | New | Elanco Animal Health Inc | $40,576,670 | – | 3,610,024 | +100.0% | 2.56% | – |
| IWM | New | IShares TRput | $39,766,500 | – | 225,000 | +100.0% | 2.51% | – |
| SNY | New | Sanofisponsored adr | $37,299,915 | – | 695,375 | +100.0% | 2.35% | – |
| New | Kenvue Inc | $36,185,847 | – | 1,802,084 | +100.0% | 2.28% | – | |
| SPY | New | SPDR S&P 500 ETF Trustput | $21,374,000 | – | 50,000 | +100.0% | 1.35% | – |
| EXEL | New | Exelixis Incput | $19,940,310 | – | 912,600 | +100.0% | 1.26% | – |
| New | Invesco QQQ TRunit ser 1 | $17,913,500 | – | 50,000 | +100.0% | 1.13% | – | |
| New | MoonLake Immunotherapeuticsclass a ord | $16,689,885 | – | 292,805 | +100.0% | 1.05% | – | |
| New | Shockwave Med Inc | $16,201,364 | – | 81,373 | +100.0% | 1.02% | – | |
| ALKS | New | Alkermes PLC | $15,054,367 | – | 537,464 | +100.0% | 0.95% | – |
| CYTK | New | Cytokinetics Incput | $14,730,000 | – | 500,000 | +100.0% | 0.93% | – |
| New | Structure Therapeutics Incsponsored ads | $10,190,840 | – | 202,119 | +100.0% | 0.64% | – | |
| CRSP | New | CRISPR Therapeutics AGput | $9,078,000 | – | 200,000 | +100.0% | 0.57% | – |
| SNDX | New | Syndax Pharmaceuticals Inccall | $8,712,000 | – | 600,000 | +100.0% | 0.55% | – |
| SNDX | New | Syndax Pharmaceuticals Incput | $6,534,000 | – | 450,000 | +100.0% | 0.41% | – |
| SRPT | New | Sarepta Therapeutics Inccall | $6,194,342 | – | 51,100 | +100.0% | 0.39% | – |
| CLDX | New | Celldex Therapeutics Incput | $5,504,000 | – | 200,000 | +100.0% | 0.35% | – |
| IMVT | New | Immunovant Inc | $5,370,185 | – | 139,885 | +100.0% | 0.34% | – |
| REPL | New | Replimune Group Incput | $5,357,141 | – | 313,100 | +100.0% | 0.34% | – |
| REPL | New | Replimune Group Inccall | $4,277,500 | – | 250,000 | +100.0% | 0.27% | – |
| AGEN | New | Agenus Inccall | $1,808,000 | – | 1,600,000 | +100.0% | 0.11% | – |
| IMTXW | New | Immatics NV*w exp 07/01/2025 | $1,128,892 | – | 318,896 | +100.0% | 0.07% | – |
| SYK | New | Stryker Corporation | $896,052 | – | 3,279 | +100.0% | 0.06% | – |
| IKNA | New | Ikena Oncology Inc | $501,033 | – | 115,712 | +100.0% | 0.03% | – |
| CBAY | New | CymaBay Therapeutics Incput | $164,606 | – | 11,040 | +100.0% | 0.01% | – |
| New | Synlogic Inc | $107,710 | – | 38,331 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.